{"name": "Idenix Pharmaceuticals",
 "permalink": "idenix-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/idenix-pharmaceuticals",
 "homepage_url": "http://www.idenix.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "idenix@idenix.com",
 "phone_number": "617-995-9800",
 "description": "",
 "created_at": "Tue Nov 30 05:24:05 UTC 2010",
 "updated_at": "Sat Apr 30 08:04:31 UTC 2011",
 "overview": "\u003Cp\u003EIdenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company\u00e2\u20ac\u2122s research and development focus is on the treatment of hepatitis C virus (HCV). In July 2009, the Company completed the proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. In October 2009, it initiated a 14-day dose-ranging phase IIa clinical trial evaluating IDX184 in combination with pegylated interferon and ribavirin in treatment-naive HCV genotype I infected patients. Idenix selected IDX320 as its lead clinical candidate from its protease inhibitor discovery program. The Company has also developed products and drug candidates for the treatment of hepatitis B virus (HBV), human immunodeficiency virus type I (HIV) and acquired immune deficiency syndrome (AIDS).\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       49],
      "assets/images/resized/0011/2224/112224v1-max-150x150.png"],
     [[212,
       70],
      "assets/images/resized/0011/2224/112224v1-max-250x250.png"],
     [[212,
       70],
      "assets/images/resized/0011/2224/112224v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Ronald",
      "last_name": "C. Renaud, Jr.",
      "permalink": "ronald-c-renaud-jr",
      "image": null}},
   {"is_past": true,
    "title": "Sr VP, Clinical Development; Chief Medical Officer",
    "person":
     {"first_name": "Nathaniel",
      "last_name": "Brown",
      "permalink": "nathaniel-brown-2",
      "image": null}},
   {"is_past": true,
    "title": "SVP, US Business Unit",
    "person":
     {"first_name": "David",
      "last_name": "Franklin",
      "permalink": "david-franklin",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$25M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2010/11/22/daily22-Idenix-HIVAIDs-treatment-trials-attract-20M-milestone-payment.html",
    "source_description": "Idenix HIV/AIDs treatment trials attract $20M milestone payment",
    "raised_amount": 20000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 11,
    "funded_day": 23,
    "investments":
     [{"company":
        {"name": "ViiV Healthcare",
         "permalink": "viiv-healthcare",
         "image":
          {"available_sizes":
            [[[88,
               76],
              "assets/images/resized/0011/2225/112225v1-max-150x150.png"],
             [[88,
               76],
              "assets/images/resized/0011/2225/112225v1-max-250x250.png"],
             [[88,
               76],
              "assets/images/resized/0011/2225/112225v1-max-450x450.png"]],
           "attribution": null}},
       "financial_org": null,
       "person": null}]},
   {"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2011/04/25/daily3-Idenix-attracts-5M-equity-financing.html",
    "source_description": "Idenix attracts $5M equity financing",
    "raised_amount": 5000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 4,
    "funded_day": 25,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "60 Hampshire Street",
    "address2": "",
    "zip_code": "02139",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "has taken in $5 million in equity fundraising",
    "stoned_year": 2011,
    "stoned_month": 4,
    "stoned_day": 25,
    "source_url": "http://www.masshightech.com/stories/2011/04/25/daily3-Idenix-attracts-5M-equity-financing.html",
    "source_text": null,
    "source_description": "Idenix attracts $5M equity financing",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Idenix Pharmaceuticals",
      "permalink": "idenix-pharmaceuticals"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:IDIX"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}